Drugs / EH002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06722170 | Nov 2024 → Nov 2027 expected | autosomal recessive nonsyndromic hearing loss 9, sensorineural hearing loss disorder | Yilai Shu | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EH002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06722170 ↗ |
| Route | Other | “EH002 was administered into one or both ears via intracochlear injection.” NCT06722170 ↗ |